Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05260307 · ClinicalTrials.gov registry record · NA

Improving Spatial Perception and Speech Understanding in Multitalker Mixtures

A NA study of Hearing Loss, sponsored by Boston University Charles River Campus.

Recruiting
Registry status
NA
Development phase
220
Enrollment target
1
Study location

NCT05260307 is a NA study of Hearing Loss that is actively recruiting participants, run by Boston University Charles River Campus. The registered enrollment target is 220 participants, below the 6,117-participant average among 58 other Hearing Loss trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05260307, a NA study of Hearing Loss, is actively recruiting participants, sponsored by Boston University Charles River Campus.

RECRUITING
Registry status
NA
Development phase
220 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate several approaches for improving spatial perception and speech intelligibility in multitalker listening situations for hearing-aid users. The hypotheses are that spatial perception and speech intelligibility will be improved by (1) increased high-frequency audibility, (2) speech envelope enhancement, and/or (3) appropriate sound image externalization.

Conditions Studied

Interventions

  • OTHER hearing aid condition

Study Locations (1)

Massachusetts

  • Boston University - Boston

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2022-03-09
Est. Completion 2026-11-30
Phase NA

What the Registry Record Tells You About NCT05260307

The ClinicalTrials.gov registry entry for NCT05260307 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,117-participant average among 58 other Hearing Loss trials with a reported enrollment target (96% lower). The listed sponsor is Boston University Charles River Campus, which has 104 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hearing Loss appearing as the primary indexed condition, and to 1 intervention - of which hearing aid condition is the first listed.

NCT05260307 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05260307 about?

NCT05260307 is a clinical study titled "Improving Spatial Perception and Speech Understanding in Multitalker Mixtures". The purpose of this study is to investigate several approaches for improving spatial perception and speech intelligibility in multitalker listening situations for hearing-aid users. The hypotheses are that spatial perception and speech intelligibility will be improved by (1) increased high-frequency...

What is the current status of trial NCT05260307?

This trial is currently recruiting. It is a NA study. The enrollment target is 220 participants. The study started on 2022-03-09. Estimated completion is 2026-11-30.

What conditions does trial NCT05260307 study?

This clinical trial studies the following conditions: Hearing Loss.

What interventions are being tested in trial NCT05260307?

The interventions under investigation include: hearing aid condition (OTHER).

Who is sponsoring clinical trial NCT05260307?

This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05260307 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hearing Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.